Table S2 shows the upregulation or downregulation of COX-2 in numerous cancers. COX-2 gene expression is significantly upregulated in cancers of the adrenal glands and papillary adenocarcinomas. The COX-2 expression is ominously downregulated in numerous types of cancers of the adrenal glands, skin, stomach testis, brain (e.g., glioblastoma) bladder, kidney (e.g., nephroblastoma and renal cell carcinoma), and ovary (e.g., cystadenocarcinoma). Here, PTGS2 is linked to cystadenocarcinoma.